Cargando…

Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars

Detalles Bibliográficos
Autores principales:	Kolberg, Hans-Christian, von Minckwitz, Gunter, Hanes, Vladimir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343751/ https://www.ncbi.nlm.nih.gov/pubmed/30713597 http://dx.doi.org/10.18632/oncotarget.26528

Ejemplares similares

Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
por: Kolberg, Hans-Christian, et al.
Publicado: (2020)

LILACS, mission and abstracts
por: Nitrini, Ricardo
Publicado: (2009)

Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
por: Kolberg, Hans-Christian, et al.
Publicado: (2021)

Synthesis and Olfactory Properties of Seco-Analogues of Lilac Aldehydes
por: Dacho, Vladimír, et al.
Publicado: (2021)

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Lilac and honeysuckle phenology data 1956–2014
por: Rosemartin, Alyssa H., et al.
Publicado: (2015)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
por: Markus, Richard, et al.
Publicado: (2017)

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
por: Markus, Richard, et al.
Publicado: (2017)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

Flower power: Locking HIV in the gut with French lilac
por: Rohr, Olivier
Publicado: (2021)

The implication of leaf anatomical structure for the selective breeding of lilacs
por: Pshennikova, L.M.
Publicado: (2021)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Clinical oncology in resource-limited settings
por: Buonaguro, Franco M, et al.
Publicado: (2013)

A Stop-Gain Mutation within MLPH Is Responsible for the Lilac Dilution Observed in Jacob Sheep
por: Posbergh, Christian J., et al.
Publicado: (2020)

Atrial fibrillation incidence and outcomes in two cohorts of octogenarians: LiLACS NZ
por: Teh, Ruth, et al.
Publicado: (2023)

Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
por: Hanes, Vladimir, et al.
Publicado: (2017)

Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars
por: Stebbing, Justin, et al.
Publicado: (2020)

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
por: Fernandes, G.S., et al.
Publicado: (2018)

End of life care preferences among people of advanced age: LiLACS NZ
por: Gott, Merryn, et al.
Publicado: (2017)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

Here to Stay: Biosimilars in Hematology
por: Gribben, John, et al.
Publicado: (2019)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

The role of biosimilars in value-based oncology care
por: Patel, Kashyap B, et al.
Publicado: (2018)

Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020)

Biosimilars in Oncology: Latest Trends and Regulatory Status
por: Joshi, Deeksha, et al.
Publicado: (2022)

Oncology biosimilars: New developments and future directions
por: Bachu, Rinda Devi, et al.
Publicado: (2022)

Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
por: Uno, Hajime, et al.
Publicado: (2019)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Financial burden among older, long‐term cancer survivors: Results from the LILAC study
por: Hastert, Theresa A., et al.
Publicado: (2018)

Dietary Protein and Transitions Between Frailty States and to Death in Advanced Age: LiLACS NZ
por: Teh, Ruth, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mhai2hn7fb4r4sd76ejp1uk3b6